Table 3.
Risk of second primary malignancies among the study population
| SPM | Observed | SIR | 95%CI | AER | P-value |
| All sites | 201 | 1.26 | 1.09-1.45 | 37.44 | 0.002 |
| Solid | 162 | 1.15 | 0.98-1.35 | 19.43 | 0.074 |
| Colorectal | 12 | 0.66 | 0.34-1.15 | -5.62 | 0.916 |
| Lung/bronchus | 31 | 1.31 | 0.89-1.86 | 6.67 | 0.133 |
| Breast | 24 | 1.06 | 0.68-1.58 | 1.29 | 0.743 |
| Prostate | 24 | 1.11 | 0.71-1.65 | 2.14 | 0.594 |
| Kidney | 10 | 2.40 | 1.15-4.42 | 5.27 | 0.014 |
| Lymphoma | 12 | 1.59 | 0.82-2.78 | 4.02 | 0.127 |
| Leukemia | 17 | 3.78 | 2.20-6.05 | 11.28 | < 0.001 |
| AML | 10 | 7.74 | 3.71-14.24 | 7.86 | < 0.001 |
AER: Absolute excess risk; SIR: Standardized incidence ratio; SPM: Second primary malignancies.